Advancements, Strategies, and Challenges in Organoid-Based Drug Evaluation for Tissue Engineering and Regenerative Medicine

Chengbin Xue; Fujia Sun; Hui Zhu; Jianfeng Shi; Jiaqi Wang; Qiuwen Sun; Muyuan Tong; Xiaosong Gu; Qianqian Han; Wei Shi

doi:10.1016/j.eng.2025.10.013

Engineering ›› DOI: 10.1016/j.eng.2025.10.013

review-article

Advancements, Strategies, and Challenges in Organoid-Based Drug Evaluation for Tissue Engineering and Regenerative Medicine

Author information +

History +

PDF (1352KB)

Abstract

Organoids, which are three-dimensional (3D) multicellular structures derived from stem cells or tissue-specific progenitors, have emerged as a transformative platform for drug evaluation within tissue engineering and regenerative medicine (TERM). These models recapitulate human tissue complexity with greater fidelity than traditional two-dimensional cultures and animal models do, offering significant advantages in predicting human-specific drug responses, enabling personalized disease modeling, and accelerating drug development. This review critically examines advances, strategies, and challenges associated with the application of organoids for drug testing in TERM. We discuss diverse organoid types, including hepatic, cardiac, neural, gastrointestinal, lung, and tumor models, and their specific applications in assessing organ-specific toxicity, drug metabolism, and multiorgan interactions. Innovative methodologies such as organ-on-a-chip integration, multiorgan systems, and 3D bioprinting are highlighted as pivotal strategies for enhancing the physiological relevance and scalability of organoid models. Despite their considerable promise, organoids present several challenges, including limitations in reproducibility, long-term culture maturity, and functional complexity. Furthermore, ethical and regulatory considerations, particularly concerning patient-derived models and genetic modifications, must be addressed to facilitate the clinical translation of organoid-based drug testing. Finally, we explore future directions, including the integration of artificial intelligence-driven predictive models, clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing, and vascularization strategies, which hold potential for overcoming existing limitations and advancing the field of drug evaluation in regenerative medicine.

Keywords

Organoids / Drug evaluation / Tissue engineering / Regenerative medicine / Personalized medicine

Cite this article

Download citation ▾

Chengbin Xue, Fujia Sun, Hui Zhu, Jianfeng Shi, Jiaqi Wang, Qiuwen Sun, Muyuan Tong, Xiaosong Gu, Qianqian Han, Wei Shi. Advancements, Strategies, and Challenges in Organoid-Based Drug Evaluation for Tissue Engineering and Regenerative Medicine. Engineering DOI:10.1016/j.eng.2025.10.013

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Tabatabaei N Rezaei, Kumar H, Liu H, Lee SS, Park SS, Kim K.Recent advances in organ-on-chips integrated with bioprinting technologies for drug screening.Adv Healthc Mater 2023; 12(20):e2203172.

[2]	Kim TY, Choi JW, Park K, Kim S, Kim JF, Park TE, et al.Lubricant-coated organ-on-a-chip for enhanced precision in preclinical drug testing.Small 2024; 20(43):e2402431.

[3]	Rimal R, Muduli S, Desai P, Marquez AB, Moller M, Platzman I, et al.Vascularized 3D human skin models in the forefront of dermatological research.Adv Healthc Mater 2024; 13(9):e2303351.

[4]	March S, Nerurkar N, Jain A, Andrus L, Kim D, Whittaker CA, et al.Autonomous circadian rhythms in the human hepatocyte regulate hepatic drug metabolism and inflammatory responses.Sci Adv 2024; 10(17):eadm9281.

[5]	Frühwein H, Paul NW.“Lost in translation?” Animal research in the era of precision medicine.J Transl Med 2025; 23(1):152.

[6]	Zhou C, Li Z, Lu K, Liu Y, Xuan L, Mao H, et al.Advances in human organs-on-chips and applications for drug screening and personalized medicine.Fundam Res 2024; 5(3):1258-1272.

[7]	Xu L, Zhou S, Dai X, Gu X, Ouyang Z.Tissue engineering and spinal cord injury repair.Engineering 2025; 46:60-72.

[8]	Man Y, Liu Y, Chen Q, Zhang Z, Li M, Xu L, et al.Organoids-on-a-chip for personalized precision medicine.Adv Healthc Mater 2024; 13(30):e2401843.

[9]	Li S, Dan X, Chen H, Li T, Liu B, Ju Y, et al.Developing fibrin-based biomaterials/scaffolds in tissue engineering.Bioact Mater 2024; 40:597-623.

[10]	Yang Q, Li M, Yang X, Xiao Z, Tong X, Tuerdi A, et al.Flourishing tumor organoids: history, emerging technology, and application.Bioeng Transl Med 2023; 8(5):e10559.

[11]	De S Beuckeleer, Van T De Looverbosch, Van J Den Daele, Ponsaerts P, De WH Vos.Unbiased identification of cell identity in dense mixed neural cultures.eLife 2025; 13:RP95273.

[12]	Liu J, Wu G, Wu D, Wu L, Sun C, Zhang W, et al.Microfluidic organoid-slice-on-a-chip system for studying anti-cholangiocarcinoma drug efficacy and hepatorenal toxicity.Lab Chip 2025; 25(12):2839-2850.

[13]	Deng ZM, Dai FF, Wang RQ, Deng HB, Yin TL, Cheng YX, et al.Organ-on-a-chip: future of female reproductive pathophysiological models.J Nanobiotechnology 2024; 22(1):455.

[14]	Loewa A, Feng JJ, Hedtrich S.Human disease models in drug development.Nat Rev Bioeng 2023; 1:1-15.

[15]	Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, et al.Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.Theranostics 2024; 14(8):3300-3316.

[16]	van AWJ Renterghem, van J de Haar, Voest EE.Functional precision oncology using patient-derived assays: bridging genotype and phenotype.Nat Rev Clin Oncol 2023; 20(5):305-317.

[17]	Shlobin NA, Savulescu J, Baum ML.The ethical landscape of human brain organoids and a mindful innovation framework.Nat Rev Bioeng 2024; 2(9):785-796.

[18]	Zushin PH, Mukherjee S, Wu JC.FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches.J Clin Invest 2023; 133(21):133.

[19]	Verstegen MMA, Coppes RP, Beghin A, De P Coppi, Gerli MFM, de N Graeff, et al.Clinical applications of human organoids.Nat Med 2025; 31(2):409-421.

[20]	Bitounis D, Jacquinet E, Rogers MA, Amiji MM.Strategies to reduce the risks of mRNA drug and vaccine toxicity.Nat Rev Drug Discov 2024; 23(4):281-300.

[21]	Ni B, Ye L, Zhang Y, Hu S, Lei W.Advances in humanoid organoid-based research on inter-organ communications during cardiac organogenesis and cardiovascular diseases.J Transl Med 2025; 23(1):380.

[22]	Han X, Cai C, Deng W, Shi Y, Li L, Wang C, et al.Landscape of human organoids: ideal model in clinics and research.Innovation 2024; 5(3):100620.

[23]	Zhu Y, Sun L, Wu X, Gu Z, Zhao Y.Engineered human organoids for biomedical applications.Adv Funct Mater 2024; 34(11):2310961.

[24]	Kim W, Gwon Y, Park S, Kim H, Kim J.Therapeutic strategies of three-dimensional stem cell spheroids and organoids for tissue repair and regeneration.Bioact Mater 2023; 19:50-74.

[25]	Huang G, Zhao Y, Chen D, Wei L, Hu Z, Li J, et al.Applications, advancements, and challenges of 3D bioprinting in organ transplantation.Biomater Sci 2024; 12(6):1425-1448.

[26]	Wu H, Feng E, Yin H, Zhang Y, Chen G, Zhu B, et al.Biomaterials for neuroengineering: applications and challenges.Regen Biomater 2025; 12:rbae137.

[27]	Tang Y, Friec AL, Chen M, Sun D.Designed biomaterial‐enhanced cell transplantation for neural tissue engineering.Aggregate 2025; 6(5):e70022.

[28]	Viegas J, Sarmento B.Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research.Adv Drug Deliv Rev 2024; 208:115295.

[29]	Sun XC, Kong DF, Zhao J, Faber KN, Xia Q, He K.Liver organoids: established tools for disease modeling and drug development.Hepatol Commun 2023; 7(4):e0105.

[30]	Zhang CJ, Meyer SR, O MJ’Meara, Huang S, Capeling MM, Ferrer-Torres D, et al.A human liver organoid screening platform for DILI risk prediction.J Hepatol 2023; 78(5):998-1006.

[31]	Salas-Silva S, Kim Y, Kim TH, Kim M, Seo D, Choi J, et al.Human chemically-derived hepatic progenitors (hCdHs) as a source of liver organoid generation: application in regenerative medicine, disease modeling, and toxicology testing.Biomaterials 2023; 303:122360.

[32]	Du X, Jia H, Chang Y, Zhao Y, Song J.Progress of organoid platform in cardiovascular research.Bioact Mater 2024; 40:88-103.

[33]	Butler D, Reyes DR.Heart-on-a-chip systems: disease modeling and drug screening applications.Lab Chip 2024; 24(5):1494-1528.

[34]	Cui X, Li X, Zheng H, Su Y, Zhang S, Li M, et al.Human midbrain organoids: a powerful tool for advanced Parkinson’s disease modeling and therapy exploration.NPJ Parkinsons Dis 2024; 10(1):189.

[35]	Birtele M, Lancaster M, Quadrato G.Modelling human brain development and disease with organoids.Nat Rev Mol Cell Biol 2025; 26(5):389-412.

[36]	Babu HWS, Kumar SM, Kaur H, Iyer M, Vellingiri B.Midbrain organoids for Parkinson’s disease (PD)—a powerful tool to understand the disease pathogenesis.Life Sci 2024; 345:122610.

[37]	Hong Y, Yang Q, Song H, Ming GL.Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells.Mol Psychiatry 2023; 28(4):1430-1439.

[38]	Shan L, Heusinkveld HJ, Paul KC, Hughes S, Darweesh SKL, Bloem BR, et al.Towards improved screening of toxins for Parkinson’s risk.NPJ Parkinsons Dis 2023; 9(1):169.

[39]	Eicher AK, Kechele DO, Sundaram N, Berns HM, Poling HM, Haines LE, et al.Functional human gastrointestinal organoids can be engineered from three primary germ layers derived separately from pluripotent stem cells.Cell Stem Cell 2022; 29(1):36-51.e36.

[40]	Kim S, Min S, Choi YS, Jo SH, Jung JH, Han K, et al.Tissue extracellular matrix hydrogels as alternatives to Matrigel for culturing gastrointestinal organoids.Nat Commun 2022; 13(1):1692.

[41]	Mitrofanova O, Nikolaev M, Xu Q, Broguiere N, Cubela I, Camp JG, et al.Bioengineered human colon organoids with in vivo-like cellular complexity and function.Cell Stem Cell 2024; 31(8):1175-1186.e7.

[42]	Kang EJ, Kim JH, Kim YE, Lee H, Jung KB, Chang DH, et al.The secreted protein Amuc_1409 from Akkermansia muciniphila improves gut health through intestinal stem cell regulation.Nat Commun 2024; 15(1):2983.

[43]	Matkovic I Leko, Schneider RT, Thimraj TA, Schrode N, Beitler D, Liu HY, et al.A distal lung organoid model to study interstitial lung disease, viral infection and human lung development.Nat Protoc 2023; 18(7):2283-2312.

[44]	Lim K, Donovan AP, Tang W, Sun D, He P, Pett JP, et al.Organoid modeling of human fetal lung alveolar development reveals mechanisms of cell fate patterning and neonatal respiratory disease.Cell Stem Cell 2023; 30(1):20-37.e29.

[45]	Liu X, Wang X, Wu X, Zhan S, Yang Y, Jiang C.Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy.Stem Cell Res Ther 2025; 16(1):29.

[46]	Zhang X, Liu H, Cheng H, Cui Y, Wang J, Yao Q, et al.In vitro biomimetic models for respiratory diseases: progress in lung organoids and lung-on-a-chip.Stem Cell Res Ther 2025; 16(1):415.

[47]	Polak R, Zhang ET, Kuo CJ.Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment.Nat Rev Cancer 2024; 24(8):523-539.

[48]	Smabers LP, Wensink E, Verissimo CS, Koedoot E, Pitsa KC, Huismans MA, et al.Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.J Exp Clin Cancer Res 2024; 43(1):61.

[49]	Peng Z, Lv X, Sun H, Zhao L, Huang S.3D tumor cultures for drug resistance and screening development in clinical applications.Mol Cancer 2025; 24(1):93.

[50]	Afonso MB, Marques V, van SWC Mil, Rodrigues CMP.Human liver organoids: from generation to applications.Hepatology 2024; 79(6):1432-1451.

[51]	Kong W, Frouard J, Xie G, Corley MJ, Helmy E, Zhang G, et al.Neuroinflammation generated by HIV-infected microglia promotes dysfunction and death of neurons in human brain organoids.PNAS Nexus 2024; 3(5):179.

[52]	Nani JV, Muotri AR, Hayashi MA.Peering into the mind: unraveling schizophrenia’s secrets using models.Mol Psychiatry 2024; 30(2):659-678.

[53]	De J Castilhos, Tillmanns K, Blessing J, Laraño A, Borisov V, Stein-Thoeringer CK.Microbiome and pancreatic cancer: time to think about chemotherapy.Gut Microbes 2024; 16(1):2374596.

[54]	Alnasser SM.From gut to liver: organoids as platforms for next-generation toxicology assessment vehicles for xenobiotics.Stem Cell Res Ther 2025; 16(1):150.

[55]	Yin X, Li Q, Shu Y, Wang H, Thomas B, Maxwell JT, et al.Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.J Biomed Sci 2024; 31(1):47.

[56]	Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C.Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research.Int J Biol Sci 2024; 20(13):5293-5311.

[57]	Moss SP, Bakirci E, Feinberg AW.Engineering the 3D structure of organoids.Stem Cell Reports 2025; 20(1):102379.

[58]	Wheeler EE, Leach JK.Tissue-engineered three-dimensional platforms for disease modeling and therapeutic development.Tissue Eng Part B Rev 2025; 31:390-405.

[59]	Wang H, Ning X, Zhao F, Zhao H, Li D.Human organoids-on-chips for biomedical research and applications.Theranostics 2024; 14(2):788-818.

[60]	Ortega JS, Corrales-Orovio R, Ralph P, Egana JT, Gentile C.Photosynthetic microorganisms for the oxygenation of advanced 3D bioprinted tissues.Acta Biomater 2023; 165:180-196.

[61]	Fang Y, Guo Y, Wu B, Liu Z, Ye M, Xu Y, et al.Expanding embedded 3D bioprinting capability for engineering complex organs with freeform vascular networks.Adv Mater 2023; 35(22):e2205082.

[62]	Akter MZ, Tufail F, Ahmad A, Oh YW, Kim JM, Kim S, et al.Harnessing native blueprints for designing bioinks to bioprint functional cardiac tissue.iScience 2025; 28(3):111882.

[63]	Ko J, Park D, Lee J, Jung S, Baek K, Sung KE, et al.Microfluidic high-throughput 3D cell culture.Nat Rev Bioeng 2024; 2(6):453-469.

[64]	Wang P, Wang Y, Qin J.Multi-organ microphysiological system: a new paradigm for COVID-19 research.Organs Chip 2023; 5:100029.

[65]	Deng S, Li C, Cao J, Cui Z, Du J, Fu Z, et al.Organ-on-a-chip meets artificial intelligence in drug evaluation.Theranostics 2023; 13(13):4526-4558.

[66]	Zhao Y, Landau S, Okhovatian S, Liu C, Lu RXZ, Lai BFL, et al.Integrating organoids and organ-on-a-chip devices.Nat Rev Bioeng 2024; 2(7):588-608.

[67]	Chen Z, Sugimura R, Zhang YS, Ruan C, Wen C.Organoids in concert: engineering in vitro models toward enhanced fidelity.Aggregate 2024; 5(2):e478.

[68]	Huang Y, Zhang P, Wang H, Chen Y, Liu T, Luo X.Genetic code expansion: recent developments and emerging applications.Chem Rev 2025; 125(2):523-598.

[69]	Zhu Y, Jiang D, Qiu Y, Liu X, Bian Y, Tian S, et al.Dynamic microphysiological system chip platform for high-throughput, customizable, and multi-dimensional drug screening.Bioact Mater 2024; 39:59-73.

[70]	Choi YM, Lee H, Ann M, Song M, Rheey J, Jang J.3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation.Biofabrication 2023; 15(3):034104.

[71]	Wang H, Li X, Shi P, You X, Zhao G.Establishment and evaluation of on-chip intestinal barrier biosystems based on microfluidic techniques.Mater Today Bio 2024; 26:101079.

[72]	Zarkoob H, Allu Aé-Guardia, Chen YC, Garcia-Vilanova A, Jung O, Coon S, et al.Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents.Commun Biol 2022; 5(1):810.

[73]	Li J, Wu Z, Gan J, Zhi Y, Zhao Y, Li L.Engineering microfluidic human liver–islet crosstalk platform for recapitulating MASLD.Chem Eng J 2025; 519:165209.

[74]	Kim J, Yoon T, Lee S, Kim PJ, Kim Y.Reconstitution of human tissue barrier function for precision and personalized medicine.Lab Chip 2024; 24(14):3347-3366.

[75]	Brandauer K, Schweinitzer S, Lorenz A, Krauss J, Schobesberger S, Frauenlob M, et al.Advances of dual-organ and multi-organ systems for gut, lung, skin and liver models in absorption and metabolism studies.Lab Chip 2025; 25(6):1384-1403.

[76]	Ingber DE.Human organs-on-chips for disease modelling, drug development and personalized medicine.Nat Rev Genet 2022; 23(8):467-491.

[77]	Yang J, Zhang X, Liu Z, Yang C, Li S, Zhou H, et al.The impact of emerging contaminants exposure on human health effects: a review of organoid assessment models.Chem Eng J 2024; 498:155882.

[78]	Kim J, Kim JS, Kim D, Bello AB, Kim BJ, Cha BH, et al.Therapeutic potential of mesenchymal stem cells from human iPSC-derived teratomas for osteochondral defect regeneration.Bioeng Transl Med 2024; 9(2):e10629.

[79]	Hirami Y, Mandai M, Sugita S, Maeda A, Maeda T, Yamamoto M, et al.Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa.Cell Stem Cell 2023; 30(12):1585-1596.e6.

[80]	Norlander AE, Basile DP.ST2⁺ T-regulatory cells as a potential immunotherapy target for kidney fibrosis.J Am Soc Nephrol 2025; 36(1):7-9.

[81]	Li Y, Xu C, Zhou X, Li J, Xu S, Tu Y, et al.DNA adductomics aided rapid screening of genotoxic impurities using nucleosides and 3D bioprinted human liver organoids.Talanta 2024; 273:125902.

[82]	Wang Y, Hou Y, Hao T, Garcia-Contreras M, Li G, Cretoiu D, et al.Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases.Biomater Transl 2024; 5:337-354.

[83]	Xia Y, Sun M, Huang H, Jin WL.Drug repurposing for cancer therapy.Signal Transduct Target Ther 2024; 9(1):92.

[84]	Wei X, Qiu J, Lai R, Wei T, Lin Z, Huang S, et al.A human organoid drug screen identifies α2-adrenergic receptor signaling as a therapeutic target for cartilage regeneration.Cell Stem Cell 2024; 31(12):1813-1830.e8.

[85]	Kim SK, Seo S, Stein-O G’Brien, Jaishankar A, Ogawa K, Micali N, et al.Individual variation in the emergence of anterior-to-posterior neural fates from human pluripotent stem cells.Stem Cell Reports 2024; 19(9):1336-1350.

[86]	Yang R, Qi Y, Zhang X, Gao H, Yu Y.Living biobank: standardization of organoid construction and challenges.Chin Med J 2024; 137(24):3050-3060.

[87]	Martins-Costa C, Pham VA, Sidhaye J, Novatchkova M, Wiegers A, Peer A, et al.Morphogenesis and development of human telencephalic organoids in the absence and presence of exogenous extracellular matrix.EMBO J 2023; 42(22):e113213.

[88]	Gu Y, Zhang W, Wu X, Zhang Y, Xu K, Su J.Organoid assessment technologies.Clin Transl Med 2023; 13(12):e1499.

[89]	Artegiani B, Hendriks D.Organoids from pluripotent stem cells and human tissues: when two cultures meet each other.Dev Cell 2025; 60(4):493-511.

[90]	Prondzynski M, Berkson P, Trembley MA, Tharani Y, Shani K, Bortolin RH, et al.Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems.Nat Commun 2024; 15(1):5929.

[91]	Zieger V, Frejek D, Zimmermann S, Miotto GAA, Koltay P, Zengerle R, et al.Towards automation in 3D cell culture: selective and gentle high-throughput handling of spheroids and organoids via novel pick-flow-drop principle.Adv Healthc Mater 2024; 13(9):e2303350.

[92]	Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, et al.Drug screening at single-organoid resolution via bioprinting and interferometry.Nat Commun 2023; 14(1):3168.

[93]	Hotta A, Schrepfer S, Nagy A.Genetically engineered hypoimmunogenic cell therapy.Nat Rev Bioeng 2024; 2:960-979.

[94]	Murphy AR, Allenby MC.In vitro microvascular engineering approaches and strategies for interstitial tissue integration.Acta Biomater 2023; 171:114-130.

[95]	Nwokoye PN, Abilez OJ.Bioengineering methods for vascularizing organoids.Cell Rep Methods 2024; 4(6):100779.

[96]	Rouleau N, Murugan NJ, Kaplan DL.Functional bioengineered models of the central nervous system.Nat Rev Bioeng 2023; 1(4):252-270.

[97]	Wang Z, Kelley SO.Microfluidic technologies for enhancing the potency, predictability and affordability of adoptive cell therapies.Nat Biomed Eng 2025; 9(6):1-19.

[98]	Velasco V, Shariati SA, Esfandyarpour R.Microtechnology-based methods for organoid models.Microsyst Nanoeng 2020; 6(1):76.

[99]	Kang SY, Kimura M, Shrestha S, Lewis P, Lee S, Cai Y, et al.A pillar and perfusion plate platform for robust human organoid culture and analysis.Adv Healthc Mater 2024; 13(21):2302502.

[100]

Pa SPșca, Arlotta P, Bateup HS, Camp JG, Cappello S, Gage FH, et al.A framework for neural organoids, assembloids and transplantation studies.Nature 2025; 639(8054):315-320.

[101]

Li P, Huang M, Li M, Li G, Ma Y, Zhao Y, et al.Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.J Exp Clin Cancer Res 2025; 44(1):72.

[102]

Andreatta F, Hendriks D, Artegiani B.Human organoids as an emerging tool for genome screenings.Annu Rev Biomed Eng 2025; 27(1):157-183.

[103]

Lovell-Badge R, Anthony E, Barker RA, Bubela T, Brivanlou AH, Carpenter M, et al.ISSCR guidelines for stem cell research and clinical translation: the 2021 update.Stem Cell Reports 2021; 16(6):1398-1408.

[104]

Hyun I, Scharf-Deering JC, Lunshof JE.Ethical issues related to brain organoid research.Brain Res 2020; 1732:146653.

[105]

Sawai T, Sakaguchi H, Thomas E, Takahashi J, Fujita M.The ethics of cerebral organoid research: being conscious of consciousness.Stem Cell Reports 2019; 13(3):440-447.

[106]

Martins F, Ribeiro MHL.Quality and regulatory requirements for the manufacture of master cell banks of clinical grade IPSCS: the EU and USA perspectives.Stem Cell Rev Rep 2025; 21(3):645-679.

[107]

Koplin JJ, Savulescu J.Moral limits of brain organoid research.J Law Med Ethics 2019; 47(4):760-767.

[108]

Jin Y, Li F, Li Z, Ikezu TC, O J’Leary, Selvaraj M, et al.Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs.Sci Adv 2024; 10(37):eadk3700.

[109]

Reyes DR, Esch MB, Ewart L, Nasiri R, Herland A, Sung K, et al.From animal testing to in vitro systems: advancing standardization in microphysiological systems.Lab Chip 2024; 24(5):1076-1087.

[110]

Fosse V, Oldoni E, Bietrix F, Budillon A, Daskalopoulos EP, Fratelli M, et al.Recommendations for robust and reproducible preclinical research in personalised medicine.BMC Med 2023; 21(1):14.

[111]

Farahany NA, Greely HT, Hyman S, Koch C, Grady C, Pasca SP, et al.The ethics of experimenting with human brain tissue.Nature 2018; 556(7702):429-432.

[112]

Osaki T, Duenki T, Chow SYA, Ikegami Y, Beaubois R, Levi T, et al.Complex activity and short-term plasticity of human cerebral organoids reciprocally connected with axons.Nat Commun 2024; 15(1):2945.

[113]

Bredenoord AL, Clevers H, Knoblich JA.Human tissues in a dish: The research and ethical implications of organoid technology.Science 2017; 355:eaaf9414.

[114]

Johnston J, Hyun I, Neuhaus CP, Maschke KJ, Marshall P, Craig KP, et al.Clarifying the ethics and oversight of chimeric research.Hastings Cent Rep 2022; 52(S2 Suppl 2):S2-S23.

[115]

Bai L, Wu Y, Li G, Zhang W, Zhang H, Su J.AI-enabled organoids: construction, analysis, and application.Bioact Mater 2024; 31:525-548.

[116]

Wang H, Li X, You X, Zhao G.Harnessing the power of artificial intelligence for human living organoid research.Bioact Mater 2024; 42:140-164.

[117]

Leng Y, Li X, Zheng F, Liu H, Wang C, Wang X, et al.Advances in in vitro models of neuromuscular junction: focusing on organ-on-a-chip, organoids, and biohybrid robotics.Adv Mater 2023; 35(41):e2211059.

[118]

Gonzales-Aloy E, Ahmed-Cox A, Tsoli M, Ziegler DS, Kavallaris M.From cells to organoids: the evolution of blood–brain barrier technology for modelling drug delivery in brain cancer.Adv Drug Deliv Rev 2023; 196:114777.

[119]

Geurts MH, Clevers H.CRISPR engineering in organoids for gene repair and disease modelling.Nat Rev Bioeng 2023; 1(1):32-45.

[120]

Vandana JJ, Manrique C, Lacko LA, Chen S.Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation.Cell Stem Cell 2023; 30(5):571-591.

[121]

Bu W, Creighton CJ, Heavener KS, Gutierrez C, Dou Y, Ku AT, et al.Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice.Sci Adv 2023; 9(19):eade0059.

[122]

Wu Y, Ye W, Gao Y, Yi Z, Chen Z, Qu C, et al.Application of organoids in regenerative medicine.Stem Cells 2023; 41(12):1101-1112.

[123]

Wang F, Song P, Wang J, Wang S, Liu Y, Bai L, et al.Organoid bioinks: construction and application.Biofabrication 2024; 16(3):032006.

[124]

Del C Amo, Andia I.Blood-derived biomaterials for tissue graft biofabrication by solvent-based extrusion bioprinting.Int J Bioprint 2023; 9(5):762.

[125]

Kerr CM, Silver SE, Choi YS, Floy ME, Bradshaw AD, Cho SW, et al.Decellularized heart extracellular matrix alleviates activation of hiPSC-derived cardiac fibroblasts.Bioact Mater 2024; 31:463-474.

[126]

Chen J, Ma S, Yang H, Liang X, Yao H, Guo B, et al.Generation and metabolomic characterization of functional ductal organoids with biliary tree networks in decellularized liver scaffolds.Bioact Mater 2023; 26:452-464.

[127]

Hendriks D, Artegiani B, Margaritis T, Zoutendijk I, de C Sousa, Lopes S, et al.Mapping of mitogen and metabolic sensitivity in organoids defines requirements for human hepatocyte growth.Nat Commun 2024; 15(1):4034.

[128]

Hong ZX, Zhu ST, Li H, Luo JZ, Yang Y, An Y, et al.Bioengineered skin organoids: from development to applications.Mil Med Res 2023; 10(1):40.

[129]

Yan J, Ye Z, Lu Y, Yuan Y, Wang X, Yan T, et al.3D bioprinting lobule-like hepatorganoids with induced vascularization for orthotopic implantation.Mater Today Bio 2025; 31:101515.

[130]

Cohen PJR, Luquet E, Pletenka J, Leonard A, Warter E, Gurchenkov B, et al.Engineering 3D micro-compartments for highly efficient and scale-independent expansion of human pluripotent stem cells in bioreactors.Biomaterials 2023; 295:122033.

[131]

Yuan X, Wu J, Sun Z, Cen J, Shu Y, Wang C, et al.Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure.Cell Stem Cell 2024; 31(4):484-498.e5.

[132]

Addissouky TA, Ali MM, El IET Sayed, Wang Y, El A Baz, Elarabany N, et al.Preclinical promise and clinical challenges for innovative therapies targeting liver fibrogenesis.Arch Gastroent Res 2023; 4(1):14-23.

[133]

Park TY, Jeon J, Cha Y, Kim KS.Past, present, and future of cell replacement therapy for Parkinson’s disease: a novel emphasis on host immune responses.Cell Res 2024; 34(7):479-492.

[134]

Yao Q, Cheng S, Pan Q, Yu J, Cao G, Li L, et al.Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.MedComm 2024; 5(10):e735.

[135]

Zhu Z, Hu E, Shen H, Tan J, Zeng S.The functional and clinical roles of liquid biopsy in patient-derived models.J Hematol Oncol 2023; 16(1):36.

[136]

Ren X, Huang M, Weng W, Xie Y, Wu Y, Zhu S, et al.Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application.Cell Rep Med 2023; 4(11):101277.

[137]

Huang Z, Jia K, Tan Y, Yu Y, Xiao W, Zhou X, et al.Advances in cardiac organoid research: implications for cardiovascular disease treatment.Cardiovasc Diabetol 2025; 24(1):25.

[138]

Cartry J, Bedja S, Boileve A, Mathieu JRR, Gontran E, Annereau M, et al.Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.J Exp Clin Cancer Res 2023; 42(1):281.

[139]

Song M, Choi DB, Im JS, Song YN, Kim JH, Lee H, et al.Modeling acute myocardial infarction and cardiac fibrosis using human induced pluripotent stem cell-derived multi-cellular heart organoids.Cell Death Dis 2024; 15(5):308.

[140]

Ortuno-Costela MC, Pinzani M, Vallier L.Cell therapy for liver disorders: past, present and future.Nat Rev Gastroenterol Hepatol 2025; 22(5):329-342.

[141]

Kim Y, Kang M, Mamo MG, Adisasmita M, Huch M, Choi D.Liver organoids: current advances and future applications for hepatology.Clin Mol Hepatol 2025; 31(Suppl):S327-S348.

[142]

Summers RA, Fagiani F, Rowitch DH, Absinta M, Reich DS.Novel human iPSC models of neuroinflammation in neurodegenerative disease and regenerative medicine.Trends Immunol 2024; 45(10):799-813.

[143]

Bellotti C, Samudyata S, Thams S, Sellgren CM, Rostami E.Organoids and chimeras: the hopeful fusion transforming traumatic brain injury research.Acta Neuropathol Commun 2024; 12(1):141.